Abstract
Background Three-dimensional (3D) echocardiography-derived right ventricular (RV) ejection fraction (EF) and global longitudinal strain (GLS) are valuable RV functional markers; nevertheless, they are substantially load-dependent. Global myocardial work index (GMWI) adjusts myocardial deformation to instantaneous pressure; therefore, it may better reflect contractility. Accordingly, we aimed to calculate RV GMWI using 3D echocardiography and examine its relationship with RV contractility’s gold standard invasive measurement.
Methods Sixty patients (65±14 years, 65% female) with suspected or established pulmonary hypertension were enrolled. Detailed 3D echocardiography was performed to quantify RV EF and GLS using the ReVISION software. Patients underwent RV pressure-conductance catheterization to obtain the RV pressure curve and to assess contractility (end-systolic elastance - Ees) and ventriculo-arterial coupling (Ees/arterial elastance - Ees/Ea). RV GMWI was calculated using the RV GLS and the RV pressure trace curve.
Results While neither RV EF (r=-0.143, p=0.275) nor GLS (r=-0.067, p=0.611) correlated with Ees, GMWI showed a strong correlation with it (r=0.669, p<0.001). In contrast, RV EF and GLS showed a relationship with Ees/Ea (RVEF: r=0.552; GLS: r=0.460, both p<0.001). By dividing the population based on the Reveal Lite 2 risk classification, EF and GLS showed a significant decrease only in the high-risk group (low vs. intermediate vs. high risk; EF: 48.8±6.6 vs. 44.0±9.4 vs. 35.0±7.8%, ANOVA p<0.001; GLS: 18.6±3.6 vs. 17.0±4.5 vs. 13.3±3.9%, ANOVA p<0.001), whereas GMWI already showed an increase in the intermediate group (550±267 vs. 831±361 vs. 797±265 mmHg%, ANOVA p<0.01).
Conclusions RV EF and GLS reflect ventriculo-arterial coupling, while GMWI strongly correlates with contractility. RV GMWI may emerge as a useful clinical tool for risk stratification and follow-up in patients with pulmonary hypertension.
Competing Interest Statement
Dr Rako, Ms Yildiz, Mr da Rocha and Dr Kremer report nonfinancial support from the University of Giessen during the conduct of the study. Dr Yogeswaran reports nonfinancial support from the University of Giessen during the conduct of the study and personal fees from MSD outside the current study. Dr Lakatos, Mr. Szijarto, Dr Fabian, and Dr Kovacs report personal fees from Argus Cognitive, Inc. during the conduct of the study. Dr Ghofrani reports nonfinancial support from the University of Giessen and grants from the German Research Foundation during the conduct of the study and personal fees from Bayer, Actelion, Pfizer, Merck, GSK and Takeda, grants and personal fees from Novartis, Bayer HealthCare and Encysive/Pfizer, and grants from Aires, the German Research Foundation, Excellence Cluster Cardiopulmonary Research, and the German Ministry of Education and Research outside the current study. Dr Seeger reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the current study and personal fees from Pfizer and Bayer Pharma AG outside the submitted work. Dr Gall reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the current study and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the current study. Dr Richter reports nonfinancial support from the University of Giessen during the conduct of the current study and research support from United Therapeutics and Bayer, speaker honoraria from Bayer, Actelion, Mundipharma, Roche, and OMT, and consultancy fees from Bayer outside the submitted work.
Funding Statement
This study was funded by Deutsche Forschungsgesellschaft, Grant Agreement Number CRC 1213, Project B08. Project number RRF-2.3.1-21-2022-00003 has been implemented with support from the European Union. Dr. Kovacs was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research constitutes a post-hoc analysis of data collected from the EXERTION study (ClinicalTrials.gov Identifier: NCT04663217). The study adhered to the principles outlined in the Declaration of Helsinki and was approved by the local Ethics Committee of the Faculty of Medicine at the University of Giessen (Approval Number: 117/16).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Disclosures and funding: This study was funded by Deutsche Forschungsgesellschaft, Grant Agreement Number CRC 1213, Project B08. Project number RRF-2.3.1-21-2022-00003 has been implemented with support from the European Union. Dr. Kovács was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences.
Dr Rako, Ms Yildiz, Mr da Rocha and Dr Kremer report nonfinancial support from the University of Giessen during the conduct of the study. Dr Yogeswaran reports nonfinancial support from the University of Giessen during the conduct of the study and personal fees from MSD outside the current study. Dr Lakatos, Mr. Szijártó, Dr Fábián, and Dr Kovács report personal fees from Argus Cognitive, Inc. during the conduct of the study. Dr Ghofrani reports nonfinancial support from the University of Giessen and grants from the German Research Foundation during the conduct of the study and personal fees from Bayer, Actelion, Pfizer, Merck, GSK and Takeda, grants and personal fees from Novartis, Bayer HealthCare and Encysive/Pfizer, and grants from Aires, the German Research Foundation, Excellence Cluster Cardiopulmonary Research, and the German Ministry of Education and Research outside the current study. Dr Seeger reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the current study and personal fees from Pfizer and Bayer Pharma AG outside the submitted work. Dr Gall reports grants from the German Research Foundation and nonfinancial support from the University of Giessen during the conduct of the current study and personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the current study. Dr Richter reports nonfinancial support from the University of Giessen during the conduct of the current study and research support from United Therapeutics and Bayer, speaker honoraria from Bayer, Actelion, Mundipharma, Roche, and OMT, and consultancy fees from Bayer outside the submitted work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
